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A B S T R A C T
Interferon gamma (IFNg) is a pro-inﬂammatory cytokine, ﬁrst described as a secreted molecule capable
of interfering with viral replication. Since then, numerous other important actions in the context of the
immune response to invading pathogens (including those invading the brain) have been ascribed to this
pleiotropic cytokine. Nevertheless, the precise role of IFNg in neuropsychiatric and neurodegenerative
disorders, and its possible contribution to the regulation of normal brain function, remains enigmatic.
This review integrates and considers current knowledge about IFNg actions with accumulating
evidence of its importance on neurocytogenesis, synaptic plasticity and neurodegeneration within the
framework of brain health and disease.
© 2017 Elsevier Ltd. All rights reserved.
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In any history of the cytokines, the 1957 discovery by Alik Isaacs
and Jean Lindenman would be a major chapter. These virologists
ﬁrst described “interferon” (IFN) – a released substance that can
interfere with subsequent viral infections to promote survival of
the invaded cell (Isaacs and Lindenmann, 1957). Just a few years
later IFN was puriﬁed and shown to exist in three isoforms: IFNa,
IFNb (the type I IFNs) and IFN g (type II IFN); the last was identiﬁed
by Wheelock (Wheelock, 1965).
IFNg is a pro-inﬂammatory cytokine; it is produced by a
restricted set of peripheral cells, such as T lymphocytes, natural
killer (NK) and NKT cells (Kasahara et al., 1983; Ye et al., 1995), but
also by central nervous system (CNS) cells in response to speciﬁc
stimuli (as discussed in a following section dedicated to IFNg-
producing cells).
Since its initial description as a viral replication inhibitor, IFNg
has been associated with a variety of functions related to the
immune response to infection (especially to intracellular patho-
gens) as well as to anti-tumoural defence. The cytokine has since
been recognized to be important for both, the innate and adaptive
components of the immune system. It is implicated in an array of
immune responses, among others, macrophage activation (Mosser,
2003), up-regulation of expression of the major histocompatibility
complex (MHC) (Giroux et al., 2003), and modulation of the type of
T helper (Th) response (Bradley et al., 1996; Smeltz et al., 2002).
Since T, NK and NKT cells are scarce in healthy brain
parenchyma, IFNg is thought to only play a role in brain function
under pathological conditions such as CNS infections, inﬂamma-
tory diseases (Olsson et al., 1990; Panitch et al., 1987; Traugott and
Lebon, 1988), trauma (Lau and Yu, 2001) and stroke (Seifert et al.,
2014; Yilmaz et al., 2006). More recently, IFNg has been implicated
in several neuropsychiatric and neurodegenerative disorders in
which inﬂammation is thought to be an important component. In
addition, IFNg has been shown to inﬂuence the mechanisms of
neural cell genesis and synaptic plasticity that are fundamental for
normal brain physiology, suggesting that its biological functions
extend beyond the boundaries of the immune response.
These newly-ascribed functions of IFNg justify a revisitation to
the original concepts that restricted neuroscientiﬁc interest in this
cytokine for more than 50 years. This review intends to integrate
knowledge of the established biology of IFNg with emerging
concepts about its role in maintaining constant dialogue between
the nervous and immune systems under physiological and
pathological conditions.
2. Revisiting IFNg
2.1. IFNg cell signalling
IFNg classically acts by binding to its receptor (IFNgR) – a
multimeric complex composed of two chains, the cell-surface
a-chain and a transmembrane b-chain. The a-chain of IFNgR
binds IFNg with high afﬁnity, triggering its dimerization with the
b-chain of IFNgR, and induction of a signalling cascade that
involves activation of Janus kinase (JAK)-signal transducer and
activator of transcription (JAK-STAT) pathway. JAK-1 associates
with the IFNgR a-chain while JAK-2 associates with b-chain.Activation of both JAK 1 and 2 leads to the phosphorylation of
(STAT)-1a which, in turn, binds to the g-interferon activation site
(GAS), a speciﬁc DNA response element present in more than 200
IFNg-responsive genes (Popko et al., 1997). In addition, IFNg can
activate other signalling pathways such as CRK – a nuclear adaptor
protein for STAT5 and phosphatidylinositol 3-kinase (PI3K), which
are important for the regulation of the cell cycle and differentia-
tion.
The multi-functionality of IFNg can be partially attributed to
the large number of IFNg-responsive genes and signalling
cascades. This multiplicity of downstream effectors may be
similarly responsible for the large number of outcomes (“inter-
ferences”) with respect to brain function, as will be discussed in
Section 3.
2.2. IFNg-producing cells
The classical sources of IFNg are T, NK and NKT cells. However,
as mentioned before, speciﬁc stimuli can induce IFNg production
by other cells types. For example, macrophages, which crucially
depend on IFNg for their activation, are now known to respond to
interleukin (IL)-12 and/or IL-18 stimulation with increased IFNg
production (Fig. 1); while IL-12 and IL-18 stimulate IFNg on their
own, their simultaneous presence has an ampliﬁed effect (Munder
et al., 1998). Moreover, macrophage-derived IFNg positively drives
IFNg production by macrophages through an autocrine mecha-
nism (Munder et al., 1998).
Evidence that IFNg can activate microglia, the brain's resident
macrophages, prompted the question of whether microglia might
also produce IFNg. The ability of microglia to produce IFNg in
response to Toxoplasma gondii infection was conﬁrmed by the
demonstration that the infection was accompanied by intracellular
staining of IFNg in, and secretion from, CD11b+CD45low microglial
cells from infected brains; secretion was observed in vitro in the
absence of further stimulation (Fig. 1) (Suzuki et al., 2005; Wang
and Suzuki, 2007). Subsequent studies detected IFNg in the culture
medium bathing microglia exposed to lipopolysaccharide (LPS), a
component of the Gram-negative bacteria cell wall (Fig. 1) (Makela
et al., 2010). Later work showed that microglial production of IFNg
does not only depend on being triggered by an immune insult since
stimulation by IL-12 and IL-18 or IL-12 alone, leads to IFNg
production by microglial cells (Fig. 1) (Kawanokuchi et al., 2006).
Curiously, IL-12 and IL-18 also stimulate IFNg production by B
cells in vitro and in vivo (Harris et al., 2005; Yoshimoto et al., 1997).
Further, Bao et al. (2014) showed that several immune challenges
(e.g. Listeria monocytogenes, Escherichia coli, vesicular stomatitis
virus and Toll-like receptor ligands) allow B cells to mount an
immune response by producing IFNg to activate macrophages.
Besides microglia, other cells of the nervous system can also
produce IFNg (Fig. 1). For example, sensory neurons in cultured
dorsal root ganglion cultures express IFNg, detectable by
immunocytochemistry. These cells not only express IFNg but also
its cognate receptor, suggesting the potential for autocrine
regulation of IFNg expression (Neumann et al., 1997b). Other
studies showed that tumour necrosis factor (TNF)a (Xiao and Link,
1998) and traumatic and metabolic injury (Lau and Yu, 2001) cause
expression of IFNg by brain astrocytes (Fig. 1). Interestingly, Wei
et al. demonstrated that IFNg expression in the aged brain is
Fig. 1. Cell sources of IFNg in addition to T, NK and NKT cells. Studies demonstrate that, in response to speciﬁc stimulus, macrophages and B cells can produce its own IFNg. In
the nervous system, microglia, sensory neurons, astrocytes, endothelial cells from microvessels and epithelial cells from the choroid plexus (CP) have been reported to have
the ability to produce IFNg in response to speciﬁc stimulus.
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endothelial cells of microvessels (Fig. 1) (Wei et al., 2000); these
cells provide an important interface between the brain parenchy-
ma and peripheral signals. However, further research will be
needed to clarify the extent to which positive IFNg immunolabel-
ling in the CP associates with IFNg-producing T cells that reside in
the CP stromal space (Kunis et al., 2013).
An important unresolved question regarding IFNg-producing
cells concerns the comparability of IFNg production between CNS
resident cells (neurons and glia) and peripheral immune cells. To
our knowledge, the only study addressing this issue reported that,
while both microglia and macrophages express IFNg in response to
Toxoplasma infection, the magnitude of response in macrophages
is greater than that in microglia (Suzuki et al., 2005).
While the available evidence indicates that IFNg production by
CNS cells depends on speciﬁc stimuli that most likely are related to
danger signals, IFNg receptors (IFNgR) are expressed by a fargreater diversity of cell types (de Weerd and Nguyen, 2012). This
raises the possibility that signalling initiated by IFNg in the
periphery might impact on brain function, a particularly attractive
hypothesis in light of the fact that such signalling may be triggered
in the absence of an obvious immune insult, a scenario in which the
brain-barrier would be conserved.
2.3. The concept of “immune privilege”
The concept of “immune privilege” with respect to the brain
was initially based on the presence of specialized barriers, such as
the blood-brain barrier (BBB) and the blood-cerebrospinal ﬂuid
barrier (BCSFB), which “protect” the brain from peripheral
molecules that could represent insults; at that time, inﬁltration
of peripheral immune cells into the CNS was considered solely as a
pathological hallmark. Over the last 20 years, however, this
simplistic view has been challenged; the current consensus is that
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limited, speciﬁc immune cells normally populate the surrounding
areas of the brain parenchyma such as the CP, the cerebrospinal
ﬂuid (CSF) and meninges (Carrithers et al., 2002) where they
support classical brain functions and play a crucial role in immune
surveillance (Louveau et al., 2015a; Schwartz, 2015).
The CSF, produced by the CP, has a cellular composition that
differs signiﬁcantly from that of blood; it is predominantly (70%)
populated by CD4+ T cells (T helpers) and, unlike blood, has very
few granulocytes, dendritic cells and B cells (de Graaf et al., 2011;
Kivisakk et al., 2003). Memory T cells, which make up more than
90% of the CD4+ T population in CSF (de Graaf et al., 2011), are cells
that have previously encountered a cognate antigen and mount a
fast and strong immune response upon re-encountering that
antigen. Accordingly, memory T cells in the CNS are particularly
important for immune surveillance, a concept extensively de-
scribed by Ransohoff and Engelhardt (2012). Brieﬂy, memory T
cells actively patrol the CNS by circulating in the CSF through the
subarachnoid spaces where they can be re-activated by antigens
presented by meningeal myeloid cells. This active immune
surveillance is rapidly translatable into an efﬁcient immune
response when pathogens or tissue damage are sensed (Hussain
et al., 2014; Ransohoff and Engelhardt, 2012). The stroma of the CP
also has a resident population of T cells but these differ from those
found in the CSF. These so-called effector memory T cells represent
more than 90% of the CD4+ T cells in the CP stroma, and express
mainly IL-4 or IFNg at levels that exceed those found in the general
circulation and lymphoid organs (Baruch and Schwartz, 2013;
Kunis et al., 2013) (Fig. 2).
Given their abundance in different compartments surrounding
the brain, it is not surprising that several recent studies indicate a
role for T cells in normal brain functions. Ablation or reduction of T
cells in mice using pharmacological or molecular genetic
approaches has been associated with cognitive impairment, anFig. 2. Neuroimmune modulation of the CNS. Brain lymphatic vessels transport cerebros
deep cervical lymph nodes (dCLN). Brain antigens can be presented to naïve T cells at the d
IFNg in the choroid plexus (CP), transmigration of memory T cells from the blood into the C
the CNS by actively sensing the environment. At the meningeal spaces, they can encounter
activated. In addition, meningeal T cells are essential for higher brain function being the
cognitive performance.effect that was reversible by T cell replenishment (Brynskikh et al.,
2008; Derecki et al., 2010; Kipnis et al., 2004; Wolf et al., 2009; Ziv
et al., 2006). In fact, the CD4+ subset of T cells seems to be
particularly important for cognitive tasks, since speciﬁc deletion of
just this population (and not CD8+ T or B cells) resulted in severely
impaired performance in the Morris water maze test that
correlated with reduced neurogenesis (Wolf et al., 2009; Ziv
et al., 2006). The importance of T cells for cognitive processing was
further suggested by the observation that training in a cognitive
task results in an accumulation of T cells in the meninges (Derecki
et al., 2011); production of IL-4 by these cells suggested behaviour-
induced skewing of meningeal myeloid cells to an M2 phenotype
(Derecki et al., 2011). Conversely, mice in which IL-4 was deleted
(IL-4 knock-out (KO)) present a pro-inﬂammatory meningeal
milieu that correlates with poor cognitive performance (Derecki
et al., 2011). Consistent with these ﬁndings, deletion of IFNg (IFNg
KO mice) was recently reported to improve cognitive abilities with
concomitant increases in hippocampal plasticity (Monteiro et al.,
2016). Together, these studies highlight the fact cognitive
performance is determined by the state of T state activation
(and consequently the cytokines they produce), rather than the
presence or absence of T cells (Fig. 2). Importantly, the animal data
pointing to the importance of T-cells and their cytokine products in
cognitive function were recently shown to apply to humans. Using
a cohort of aged individuals Serre-Miranda and colleagues
reported that the number of CD4+ effector T cells (the subset of
T cells more likely to produce cytokines) predicts both general and
executive function and memory (Serre-Miranda et al., 2015).
The fact that the vast majority of T cells in the CNS are pre-
activated raises the important question as to how and where they
are activated. Classical T cell activation involves antigen priming:
antigens presented by specialized antigen-presenting cells (APCs)
are recognized by speciﬁc receptors on the surface of T cells. Since
transgenic mice engineered to express T cells that only recognizepinal ﬂuid (CSF) containing immune cells and also brain antigens draining it to the
CLN, that upon activation can mobilize towards the CNS. Depending on the levels of
SF can occur in a multi-step mechanism. The CSF is rich in memory T cells that patrol
 pathogens or danger signals presented by local myeloid cells and become rapidly re-
 ﬂow of T cells into the meninges but also their state of activation determinants of
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supports the view that T cells that recognize CNS-speciﬁc antigens
may be relevant for cognitive function. Interestingly, the cognitive
deﬁcits presented by mice with this limited T cell repertoire were
reduced by adoptive transfer of CD4+ T cells that speciﬁcally
recognized a peptide normally found in the CNS (Radjavi et al.,
2014b). It is important to note, however, that T and specialized
APCs are relatively scarce in the healthy brain, making antigen
presentation an unlikely event. In fact, the low level of antigen
presentation in the brain, discovered in experiments that showed
that tissue grafts in the brain survived for prolonged periods
without eliciting an immune response (Medawar, 1948) was one of
the key principles upon which the immune privileged status of the
CNS. On the other hand, while APCs are found in the meninges and
CP, active drainage of CNS antigens into the deep cervical lymph
nodes (dCLN) and the consequent development of antigen-speciﬁc
immune responses, has also been demonstrated (Walter et al.,
2006). These ﬁndings indicate that the dCLN are a likely site at
which T cells of the CNS are activated (Fig. 2). Supporting this view,
surgical removal of dCLN has been shown to interrupt the ﬂow of
CD4+ T cells into the meninges with the concomitant occurrence of
cognitive impairments (Radjavi et al., 2014a). Nevertheless, the
question of how and where these surveying and supportive
immune cells enter and leave the CNS remains open.
Three potential entry routes for peripheral T cells from the
blood to the CNS were discussed in an excellent review by
Ransohoff et al. (2003): (1) from blood to the parenchymal
perivascular space (Hickey, 1999; Piccio et al., 2002), (2) from the
blood to the subarachnoid space (Hickey,1999; Hickey and Kimura,
1988; Lassmann et al., 1993) and (3) through the CP to the CSF
(Carrithers et al., 2002). The last of these, thought to occur most
frequently under physiological conditions, is characterized by a
multi-step mechanism in which T cells travel from the blood to the
CP stroma through the fenestrated endothelium of the CP vessels,
mobilize from the stroma to the basolateral surface of CP epithelial
cells, ﬁnally reaching the CSF and the subarachnoid space in a
process involving adhesion molecules, chemokines and cytokines
(Ransohoff et al., 2003) (Fig. 2). Within the framework of this
review, it is important to note that of all the cytokines found in the
CP, IFNg proved to be a key regulator of peripheral T cells entry into
the CSF by upregulating CP epithelial cell expression of the
adhesion molecule ICAM-1 and the immune cell chemoattractants
CXCL10 and CCL6 which, together, allow the transmigration of T
cells (Chang et al., 2002) (Fig. 2). Consistent with this schema, mice
lacking IFNgR display reduced expression of molecules that
regulate immune cell trafﬁcking to the CP and therefore display
lower inﬁltration of CD4+ T cells into the CSF (Kunis et al., 2013). A
study showing that danger signals originating in the brain
parenchyma promotes leucocyte recruitment across the CP
(Baruch et al., 2015) supports the notion that the CP is crucial
for optimal immune surveillance in the CNS. Interestingly,
decreased IFNg signalling (decreased mRNA expression of IFNg-
dependent genes) in the CP is a common feature of ageing (Baruch
et al., 2014) as well as neurodegenerative disorders such as
Alzheimer's disease (Mesquita et al., 2015) and amyotrophic lateral
sclerosis (Kunis et al., 2015), underlining the importance of
appropriate immune surveillance for healthy brain functioning.
Other sites for leucocyte entry to the CNS, which may be
regulated by a similar mechanism to the one triggered by IFNg at
the CP, are also conceivable. This view receives support from the
report that co-treatment of mouse and human endothelial and BBB
cells with IFNg and TNFa, promotes leucocyte transmigration
through a mechanism that involves downregulation of a tandem
pore domain potassium channel (TREK-1) (Bittner et al., 2013).
However, it remains unclear as to whether this type of T cell
transmigration across the BBB truly represents an alternative entryroute for surveying/supportive T cells, or whether it more broadly
reﬂects pathophysiological inﬂammation-mediated breakdown of
the BBB.
Finally, the recent anatomical discovery of a brain lymphatic
system (Aspelund et al., 2015; Louveau et al., 2015b) deserves
mention because it calls for a reappraisal of the relationship
between immune cells and their associated molecular pathways in
the brain. In particular, this discovery leads to the questions of how
surveying immune cells leave the CNS and of how CSF and brain
antigens reach the dCLN. Louveau et al. and Aspelund et al.
independently demonstrated that meningeal lymphatic vessels
run along the sagittal venous sinus draining immune cells, carrying
small molecules and excess CSF from the CNS to the dCLN (Fig. 2)
(Aspelund et al., 2015; Louveau et al., 2015b). This represents a
second stage of the CNS clearance pathway that is at ﬁrst
performed by the glymphatic system. The glymphatic system
carries CSF into the brain parenchyma along a para-arterial route in
which solutes are exchanged with brain interstitial ﬂuid (ISF),
mediated by astrocytic aquaporin 4 water channels (Iliff et al.,
2012). The CSF carrying cleared soluble proteins, waste products
and excess ISF is then drained into the lymphatic system. The
lymphatic vessels leave the CNS through the foramina at the base
of the skull, alongside arteries, veins and cranial nerves, into the
dCLN (Aspelund et al., 2015; Louveau et al., 2015b) (Fig. 2). As in
other tissues, these meningeal lymphatic vessels express speciﬁc
lymphatic vessel markers such as CCL21, a chemoattractant that
binds to CCR7, which is typically expressed in memory T cells.
The discovery of the brain lymphatic system is exciting, not only
because it represents a route for specialized immune cells to
transport brain antigens into the dCLN (the classical form for CNS T
cell activation), but also because malfunction of this system can
result in the accumulation of waste products in the brain, a feature
common to many neurodegenerative diseases.
Notwithstanding the fact that the brain is immune privileged, it
is now generally recognized that healthy brain function neverthe-
less depends on neuroimmune interactions. Like other mediators,
IFNg has been demonstrated to be a key molecule in neuroimmune
communication, including the entry of T cells through the CP and
the selection/activation of distinct T cell-sub-types that impact on
cognitive function (Fig. 2).
3. Impact of IFNg in the nervous system
3.1. Inﬂuence on cell genesis
Viral replication, an important target of interferons, has
similarities with cell proliferation since it also engages the DNA
replication machinery (Tsurimoto and Stillman, 1990). Thus, it is
not altogether surprising that IFNg also modulates physiological
cell genesis (summarized in Table 1) (Fig. 3).
Mesenchymal stem cells (MSC) are adult multipotent cells that
can give rise to a variety of cell types, including neural cells
(Brazelton et al., 2000; Cogle et al., 2004). Both, mouse and human
MSC proliferation can be inhibited by IFNg, but given the scope of
this review, it is perhaps interesting to note that IFNg, by activating
indoleamine 2,3-dioxigenase (IDO) and consequently, the kynur-
enine pathway, contributes to the differentiation of human MSC
along the neural cell lineage (Croitoru-Lamoury et al., 2011).
Neural stem cells (NSC) are self-renewing cells that can give rise
to neurons, astrocytes and oligodendrocytes in response to speciﬁc
environmental stimuli. They are particularly important for neuro-
development but also exist in the adult rodent brain, primarily in
the subventricular zone (SVZ) and the subgranular zone (SGZ) of
the hippocampal dentate gyrus. Control of NSC self-renewal,
proliferation and differentiation has been attributed to several
different cytokines, including IFNg.
Table 1
Summary of the studies describing the effect of IFNg on cell genesis.
Measure Experiment Model Outcome Reference(s)
Proliferation In vitro Mesenchymal stem cells (MSC) Inhibited Croitoru-Lamoury et al. (2011)
Oligodendrocyte-type 2 astrocyte progenitor
cells (O-2A/OPCs)
Inhibited Tanner et al. (2011)
Embryonic neurospheres Enhanced Li et al. (2010)
Granule neuron precursor (GNP) Enhanced Sun et al. (2010)
In vivo Neural stem cells (NSC) from the
subventricular zone (SVZ)
Decreased Pereira et al. (2015)
Mice with pre-natal inducible-brain
expression of IFNg
Increased but dysfunctional cerebellar proliferation Wang et al. (2004)
Mice with inducible IFNg expression in
astrocytes
Cerebellar dysplasia; hypomyelination; severe
ataxia; death before puberty
Corbin et al. (1996) and LaFerla
et al. (2000)
Neurosphere
formation
In vitro NSC Inhibited Li et al. (2010) and Makela et al.
(2010)
NSC from IFNg KO Enhanced Li et al. (2010)
Differentiation In vitro MSC Enhanced Croitoru-Lamoury et al. (2011)
NSC Enhanced Kim et al. (2007)
NSC Increased but dysfunctional Walter et al. (2011)
In vivo SVZ Increased Pereira et al. (2015)
Neurogenesis In vivo IFNg KO mice Increased Li et al. (2010) and Monteiro et al.
(2016)
Alzheimer's disease model producing limiting
amounts of IFNg
Increased Baron et al. (2008) and
Mastrangelo et al. (2009)
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(Makela et al., 2010; Walter et al., 2011) and in vitro stimulation
with IFNg was shown to directly inhibit neurosphere formation
from NSC isolated from either the neonatal or adult SVZ without
the involvement of other cell types (Li et al., 2010; Makela et al.,
2010); the effects of IFNg were shown to be mediated by cyclin-
dependent kinase inhibitor p21 (Makela et al., 2010). In line with
these studies demonstrating the inhibitory actions of IFNg on
neurosphere formation, SVZ cells from IFNg KO mice were
observed to display increased self-renewal capacity and to produce
more and larger neurospheres than wild-type (WT) mice (Li et al.,
2010).
Anti-proliferative effects of IFNg were also demonstrated in
oligodendrocyte-type 2 astrocyte progenitor cells (O-2A/OPCs) in
CNS (which give rise to oligodendrocytes and astrocytes). This
could be attributed to the cytokine's ability to suppress the
expression of platelet-derived growth factor receptor (PDGFR)-a
and Ki-67, two important proliferative factors, and to induce cell
cycle by upregulating cyclin-dependent kinase inhibitor 1B
(p27Kip1) and retinoblastoma protein (Rb) (Tanner et al., 2011).
One interesting possibility that could explain the IFNg-induced
reduction of neural progenitor cells (NPCs) proliferation would be
that IFNg promotes differentiation of NPC into neurons. Kim et al.
provided evidence for this hypothesis by demonstrating that IFNg
induces neuronal differentiation (increased expression levels of
the neuronal marker bIII-tubulin) through the mediation of c-Jun
N-terminal Kinases (Kim et al., 2007). Moreover, a recent in vivo
study demonstrated that IFNg decreases proliferation of Nestin+
progenitor cells in the SVZ, while enhancing that of neuroblasts
through the mediation of STAT1 (Pereira et al., 2015) (neuroblasts
in the SVZ eventually develop into neurons as they migrate along
the rostral migratory stream into the olfactory bulb).
It has also been reported that IFNg treatment increases
neuronal differentiation in parallel with a reduction of NPC
proliferation (Walter et al., 2011). On the other hand, the
differentiation observed was dysfunctional insofar that the mature
cells aberrantly expressed both neuronal (bIII-tubulin) and glial
markers (glial ﬁbrillary acidic protein (GFAP)) (Walter et al., 2011).
For example, IFNg treatment was associated with dysregulateddownstream signalling, including an upregulation of the sonic
hedgehog (SHH) pathway and a downregulation of pro-neurogenic
factors (Pax6, Math1, Mash1 and Neurogenin1) expression (Walter
et al., 2011).
Interestingly, IFNg elicits differential responses in embryonic
neurospheres vs. postnatal or adult neurospheres; the embryonic
neurospheres proliferate in response to activation of the SHH
pathway (Li et al., 2010). Thus, in vitro treatment of granule neuron
precursor (GNP) cells with IFNg increases SHH protein expression
and an augmentation of proliferation following binding of STAT1 to
the SHH promoter; consistent with this, inhibition of SHH
signalling blunts the proliferative action of IFNg on GNP expansion
(Sun et al., 2010). Notably, inducible expression of IFNg in the
prenatal mouse brain resulted in cerebellar dysplasia characterized
by persistent and abnormal proliferation of granule neurons in the
external granule cell layer (EGL) of the cerebellum due to SHH-
mediated disrupted granular cell migration from the EGL through
the molecular layer into the internal granule cell layer (Wang et al.,
2004). Cerebellar dysplasia, together with high hypomyelination in
the cerebellum and hippocampus, was also observed in transgenic
mice expressing IFNg in the CNS or speciﬁcally in astrocytes,
respectively controlled by the myelin basic protein (MBP) (Corbin
et al., 1996) or GFAP (LaFerla et al., 2000) gene promoters. These
animals displayed severe ataxia and died before reaching sexual
maturity (Corbin et al., 1996; LaFerla et al., 2000). On the other
hand, deletion of IFNg stimulates cytogenesis (bromodeoxyuridine
(BrdU)-positive cells) and neuronal proliferation in the olfactory
bulb (Li et al., 2010) and in the dentate gyrus (Monteiro et al., 2016),
suggesting that IFNg normally acts to inhibit neurogenesis in this
brain area.
Interestingly, in animal models of Alzheimer's disease (AD), the
production of low amounts of IFNg appears to actually support
neurogenesis (Baron et al., 2008; Mastrangelo et al., 2009),
possibly by interacting with other modulators found in AD.
Another puzzling observation is that IFNg differentially affects the
fate of NSC. As opposed to its effects on neurons and oligoden-
drocytes, IFNg promotes the differentiation of astrocytes (Li et al.,
2010; Tanner et al., 2011) and, conversely, isolated neurospheres
from IFNg KO mice differentiate more readily into neurons and
Fig. 3. IFNg immune functions and their potential impact on CNS. The IFNg impact in the CNS can be related to its immune function. IFNg has an anti-proliferative function,
which in the CNS may translate in the disruption of neurogenesis. IFNg activates macrophages inducing the production of nitric oxide (NO), and similarly in the CNS it may
activate microglia to produce NO leading to neurodegeneration. The IFNg ability to induce the expression of major histocompatibility complex (MHC) I class molecules in the
CNS was long though to enable communication between brain cells and immune cells during neuroinﬂammation, however MHC I class molecules induction may as well be
involved in synaptic elimination. IFNg is known to increase the expression levels of several complement proteins, namely of C3, that was associated with tagging of synapses
for elimination.
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make it plausible that IFNg-induced astrocyte differentiation may
be related to the role of IFNg in the immune response since several
studies have demonstrated that IFNg confer astrocytes with the
ability to act as non-professional antigen-presenting cells through
an upregulation of MHC expression (Jarosinski and Massa, 2002;
Vardjan et al., 2012); however, this issue requires further
investigation.
As reviewed above, the ability of IFNg to inﬂuence cell
proliferation, differentiation and survival was demonstrated for
many neural cell types; however, the divergent cell-speciﬁc
outcomes highlight the necessity for future studies to elucidate
the conditions under which this cytokine acts to promote or inhibit
the different stages of cell genesis.3.2. Inﬂuence on synaptic plasticity
The brain is a highly dynamic structure; it can reorganize its
neural circuits to form new connections between neurons
(synapses) and/or to break others during the course of learning
a new task, in response to environmental stimuli, or as part of its
recovery from damage. Depending on their activity, synapses can
be strengthened or weakened over time, phenomena that require
both, neurotransmission and dendritic remodelling.
3.2.1. Dendritic remodelling
Dendrites are neuronal projections that receive synaptic inputs
and are critical for transmitting information. Each dendritic tree
can combine information from multiple synapses emerging from
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morphological reconﬁguration in response to received stimuli.
IFNg was shown to inﬂuence synaptic connectivity in the brain
by triggering the selective retraction of dendrites. For example,
exposure of cultured sympathetic and hippocampal neurons to
IFNg was found to lead to an 88% reduction in the length of the
dendritic tree and to inhibit synapse formation without affecting
axonal outgrowth or cell survival. These changes were ascribed to
mediation by STAT1 since cell transfection with a dominant-
negative STAT1 mutant, which cannot be phosphorylated on
Tyrosine 701, abrogated the effects of IFNg. Furthermore, exposure
of just the axonal part of these neurons to IFNg was sufﬁcient to
elicit STAT1-mediated dendritic retraction and synaptic loss (Kim
et al., 2002). Other studies suggested involvement of the Ras-like
protein in tissue (Rit)-p38 pathway in IFNg-induced dendritic
retraction since IFNg rapidly activated Rit in cultured rat
sympathetic and hippocampal neurons, while expression of a
dominant negative Rit mutant inhibited the dendritic retraction
observed after IFNg exposure (Andres et al., 2008).
Data showing that DG granule neurons in IFNg KO mice have
longer dendritic lengths and that their CA1 pyramidal neurons
present more complex dendritic trees is in line with previous
experiments showing that IFNg induces dendritic retraction
(Monteiro et al., 2016). Moreover, Filiano et al., using analysis of
resting-state blood-oxygen-level dependent (BOLD) signals, fur-
ther demonstrated hyperconnectivity between frontal to insular
regions in IFNg KO mice (Filiano et al., 2016).
Here, it is of interest to mention studies showing a crucial role
for immune molecules such as MHC I and complement proteins in
synapse pruning, a phenomenon that is essential for the
reﬁnement of neuronal circuits during neurodevelopment (Lee
et al., 2014; Schafer et al., 2012). Similar mechanisms have been
reported for synapse elimination in several diseases of the adult
brain, including Alzheimer's (Hong et al., 2016), multiple sclerosis
(Michailidou et al., 2015) and in West Nile virus infection, a disease
associated with memory loss (Vasek et al., 2016). Since IFNg levels
are altered in these disorders and because IFNg is known to induce
the expression of MHC I in neurons (Neumann et al., 1997a) and to
up-regulate the expression of complement protein 3 (C3) in human
astroglioma cells (Barnum et al., 1992), it seems plausible that
MHC1 and C3 may mediate the effects of IFNg on dendritic
retraction and synapse elimination (Fig. 3), although further
studies are needed to prove this causality.
3.2.2. Glutamatergic transmission
Glutamate is the most abundant neurotransmitter in the brain;
it is an important excitatory molecule involved in synaptic
plasticity and is considered central for learning and memory
processes. Imbalances in glutamatergic transmission can lead to
the generation of seizures and/or to excitotoxicity that is
characterized by the high inﬂux of calcium ions, which triggers
an enzymatic cascade that culminates in neuronal damage by
overexcitation. Excitoxicity is a common underlying mechanism of
neurodegenerative diseases such Alzheimer's (Guivernau et al.,
2016; Scimemi et al., 2013), Parkinson's (Armentero et al., 2006;
Hoekstra et al., 2015; Van Laar et al., 2015) and Multiple Sclerosis
(Pitt et al., 2000), among others.
The ﬁrst reports showing the association between IFNg and
excitatory activity came from in vitro experiments in which
treatment of either cultured hippocampal slices or dissociated
neurons with IFNg resulted in spontaneous excitatory activity that
eventually led to epileptic bursting (Muller et al., 1993; Vikman
et al., 2001). Curiously, the increase in excitatory activity was found
to occur slowly, being ﬁrst registered minutes (Muller et al.,1993) or
days (Vikman et al., 2001) after addition of IFNg to the culture
media, suggesting intermediation by other molecules. Reactiveoxygen species, derived from IFNg-stimulated microglia have been
suggested to be, at least partially, responsible for eliciting excitation,
since the addition of reactive oxygen species scavengers signiﬁ-
cantly blunted the effects of IFNg (Muller et al., 1993). Abnormally
high levels of IFNg in the brain, such as those observed in CNS viral
infections, have been associated with the development of seizures –
the clinical manifestation of a dysfunctional glutamatergic trans-
mission and hyperexcitability (Getts et al., 2007). Further, unlike
their WT counterparts, West Nile virus-infected IFNg KO mice do
not develop seizures even though both genotypes present similar
levels of the virus, TNFa and IL6 in the brain (Getts et al., 2007); the
latter two cytokines have been implicated in synaptic plasticity
(Balschun et al., 2004; Stellwagen and Malenka, 2006). Further, the
administration of convulsive agents to mice showed that IFNg-
induced seizures are most likely mediated through amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) or kainate
receptors (Getts et al., 2007). Importantly, administration of the
g-aminobutyric acid (GABA) antagonist, Pentylenetetrazol (PTZ),
induced seizures in both WT and IFNg mice, indicating that GABA
receptors are not involved in the IFNg-induced seizures. Although
slower in onset, the seizures induced by N-methyl-D-aspartate
(NMDA) were found to be of equal magnitude in WT and IFNg KO.
Strikingly, kainic acid-induced seizures were completely abolished
in IFNg KO mice, pointing to the involvement of either kainate
receptors or AMPA receptors (kainate binds to both, kainite and
AMPA receptors) in IFNg-induced seizures (Getts et al., 2007). In a
different study, AMPA receptors were shown to be crucial for IFNg-
induced excitotoxicity and neurodegeneration. Importantly, it was
shown that activated IFNgR can form a unique complex with the
AMPA receptor subunit GluR1, the phosphorylation of which (at
serine 845) triggers the JAK1,2/Stat1 pathway and culminates in an
inﬂux of calcium ions, production of nitric oxide and formation of
dendritic beads, a common feature of excitotoxic damage (Mizuno
et al., 2008). Pharmacological analysis suggested that the formation
of dendritic beads was mediated by activation of both, the IFNg and
AMPA/kainate (Mizuno et al., 2008).
In contrast to the upregulation of AMPA receptors observed after
acute IFNg treatment, chronic IFNg was found to reduce AMPA
receptor expression on the dendrites of hippocampal neurons
(Vikman et al., 2001); this response, which most likely represents a
defence mechanism that controls excitotoxic damage, was reported
to increase spontaneous spiking frequencyand alter gene expression
in the hypothalamic suprachiasmatic nucleus which serves to
synchronize daily physiological rhythms and which is implicated in
neurodegenerative diseases (Kwak et al., 2008). In line with other
ﬁndings described above, this IFNg-induced decrease in synaptic
plasticity does not depend on GABAergic inputs (addition of the
GABAA receptor antagonist bicuculline failed to reduce spontaneous
spiking frequency elicited by IFNg treatment).
Long-term potentiation (LTP), which occurs at excitatory
synapses, is a form of long-term plasticity that may occur over
minutes or hours; LTP underlies learning and memory acquisition.
Studies on the impact of neuroinﬂammation on the decline of LTP
during ageing in M.A. Lynch's laboratory ﬁrst showed that age-
related decreases in LTP are accompanied by increases in the
hippocampal levels of IL-1, IL-18 and IFNg (Grifﬁn et al., 2006). The
same laboratory subsequently demonstrated that intracerebro-
ventricular administration of IFNg abrogates LTP with concomitant
increases in hippocampal IL-1 levels (Maher et al., 2006).
Consistent with these data, we recently showed similar LTP
response in WT and IFNg KO mice, conﬁrming that IFNg is not
essentially linked to initiation of LTP (Monteiro et al., 2016).
3.2.3. GABAergic transmission
GABA represents the main inhibitory neurotransmitter in the
CNS. Recent studies have shown that IFNg can induce
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For example, genetic or pharmacological suppression of the
protein kinase RNA-activated (PKR), a sensor of double-stranded
RNA viruses that regulates IFNg expression (Cohen-Chalamish
et al., 2009), is accompanied by an increase on IFNg, which in turn,
induces hippocampal and cortical hyperexcitability by reducing
inhibitory GABAergic activity and enhances long-term memory
(Zhu et al., 2011). Interestingly, agonists of the benzodiazepine
receptor (an allosteric modulatory site on the GABA receptor)
inhibit IFNg production, an effect that suggests a role for IFNg in
anxiety (Wei et al., 2010). Reduced GABAergic activity has also
been observed after application of IFNg in the spinal cord dorsal
horn (Vikman et al., 2007), suggesting that IFNg may contribute to
central sensitization and persistent pain.
3.2.4. Serotonergic signalling
The monoamine neurotransmitter serotonin, synthesized from
tryptophan, is important for the regulation of mood, appetite and
sleep. The implication of IFNg in depression is based on the ability
of this cytokine to induce IDO, a rate-limiting enzyme involved in
tryptophan catabolism; modulation of IDO shifts the availability of
tryptophan away from serotonin production into the kynurenine
pathway, resulting in the generation of the neurotoxic metabolites
quinolic acid and 3-hydroxy-kinurenine. Indeed, IDO is suggested
to contribute to impaired mood and recognition memory (Heisler
and O’Connor, 2015; H. Kim et al., 2012; O’Connor et al., 2009b). In
summary, IFNg-induced depletion of serotonin, through induction
of the kynurenine pathway, is a likely mechanism that explains the
pathophysiology of ageing-related neuropsychiatric disorders and
depression (Myint et al., 2013; Oxenkrug, 2011).
3.3. Involvement in neuropsychiatric and neurodegenerative diseases
3.3.1. Neuropsychiatric alterations
Recognition that almost all neuropsychiatric disorders have an
inﬂammatory component has spurred interest in the role of
immune molecules in the pathophysiology of brain diseases.
Accordingly, the potential neuropathological contributions of IFNg
have not escaped attention. Polymorphisms in the IFNg gene and
its receptor were recently associated with the development of
schizophrenia (Jemli et al., 2016; H.J. Kim et al., 2012; Paul-
Samojedny et al., 2011) and acute manifestations of the disease
have been correlated with decreased levels of IFNg (Arolt et al.,
2000). Importantly, results of a clinical trial showed that, as
compared to placebo, inclusion of an immunomodulatory drug
that increases endogenous IFNg-production as part of a complex
therapy for schizophrenia reduces clinical symptoms (Vetlugina
et al., 2016). Furthermore, a case-report study described clinical
improvements in two antipsychotic-resistant schizophrenic
patients after addition of IFN-g-1b (a biological manufactured
protein similar to the IFNg produced by immune cells) to their
antipsychotic therapy for 4 weeks (Gruber et al., 2014).
Evidence for a role of IFNg in the pathophysiology of depression
includes the ﬁnding that serum levels of the cytokine are increased
in depressed patients (Maes et al., 1994; Schmidt et al., 2014).
Further, anti-depressants reduce serum IFNg levels and increase
those of the anti-inﬂammatory peptide interleukin IL-10 (Maes
et al., 1999). Exposure to stressors, which increases susceptibility
to develop neuropsychiatric alterations including depression, is
associated with elevated IFNg levels in the serum. For example,
medical students with greater perception of stress (when
subjected to pre-exam stress) display increased blood concen-
trations of pro-inﬂammatory cytokines, including IFNg, while
having lower levels of the anti-inﬂammatory cytokines IL-10 and
IL-4 (Maes et al., 1998). In line with these observations in humans,
exposure of IFNg KO mice to chronic mild stress is not followed byincreased blood levels of the pro-inﬂammatory cytokines TNFa
and IL-2 and does not show elevated levels of corticosterone, a
hallmark of the stress response (Litteljohn et al., 2010). Addition-
ally, chronically stressed IFNg KO mice display improved cognitive
performance when compared to WT mice (Litteljohn et al., 2014),
suggesting that IFNg may be causally involved in stress-related
cognitive deﬁcits.
Several studies have reported high blood levels of IFNg in
patients with autism spectrum disorder (El-Ansary and Al-Ayadhi,
2014; Li et al., 2009; Tostes et al., 2012). It was recently found that,
besides elevated levels of IFNg, such patients also showed
increased levels of gamma-interferon-inducible protein 16
(Iﬁ16) and reduced levels of TNFa and IL-6 (El-Ansary and Al-
Ayadhi, 2014). Interestingly, multiple regression linear analyses
identiﬁed associations between an imbalance in GABAergic and
glutamatergic synapses and IFNg and Iﬁ16 levels (El-Ansary and
Al-Ayadhi, 2014), suggesting that neuroinﬂammation related to
IFNg may contribute to synaptic dysfunction in autism spectrum
disorder.
Neuropsychiatric alterations have also been associated with
certain infectious diseases characterized by an immune response
mediated by IFNg. For instance, IFNg mRNA levels in the
hippocampus were increased in piglets infected with a porcine
reproductive and respiratory syndrome virus; these piglets also
showed decreased performance in cognitive tasks (Elmore et al.,
2014). Another example that illustrates the link between infection,
IFNg and behavioural alterations is that infection of mice with
Mycobacterium bovis Bacillus Calmette-Guérin (BCG) induces
changes in mood-like behaviour that are dependent on IFNg
(O’Connor et al., 2009a).
Data from humans, as well as animal models of various
neuropsychiatric disorders, consistently show altered levels of
IFNg. While it is not clear as to whether IFNg is beneﬁcial or
detrimental since either low or high levels are associated with
different conditions, it seems likely that at least some of the
neuropsychiatric states arise from interactions between IFNg and
speciﬁc mechanisms of each disease rather than from a primary
effect of this cytokine. Animal models in which the IFNg gene has
been deleted will prove important research tools for dissecting the
impact of IFNg in the different dimensions of behaviour that are
altered in neuropsychiatric disorders. For instance, studies with
IFNg KO mice have already shown that IFNg is important for
emotional (Campos et al., 2014; Kustova et al., 1998; Litteljohn
et al., 2010) and cognitive (Litteljohn et al., 2014; Monteiro et al.,
2016) behaviours. While the enhancement of hippocampus-
dependent cognitive behaviour in the absence of IFNg expression
was previously referred to, Monteiro and colleagues provided data
describing the structural, cellular and electrophysiological corre-
lates of the hippocampal plasticity likely to underpin the altered
behaviour (Monteiro et al., 2016).
Social deﬁcits were recently observed in mice lacking IFNg and,
conversely, transcriptomic analysis showed that IFNg-regulated
genes are enriched in mice exposed to social aggregation (or to
psychostimulants) (Filiano et al., 2016). The same authors reported
that IFNg KO mice display aberrant hyper-connectivity between
different brain regions that could underpin their impaired social
behaviour (Filiano et al., 2016). On the other hand, it is important to
note that whereas deletion IFNg produces deﬁcits in social
behaviour (Filiano et al., 2016), the absence of IFNg associates
with improved cognitive skills (Monteiro et al., 2016). Interesting-
ly, brain hyper-connectivity is a feature of children with autism
spectrum disorders (Nelson and Valakh, 2015; Supekar et al., 2013)
who besides displaying altered social behaviour also show
differences (positive and negative) in cognitive function (Pellicano,
2010). At the same time, while IFNg KO mice reproduce some of
the clinical features found in patients with autism spectrum
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Ansary and Al-Ayadhi, 2014; Li et al., 2009; Tostes et al., 2012)
points to the need for future studies which address these apparent
discrepancies.
Although it is becoming evident that IFNg has a multiplicity of
effects in the brain, particularly on social, emotional and cognitive
domains, remains much to be understood regarding the mecha-
nisms through which IFNg impacts on neuropsychiatric health and
in particular, how it interacts with other mediators of disease.
3.3.2. Neurodegenerative diseases
Neurodegenerative diseases are characterized by a slow and
progressive dysfunction and death of neurons, a process common-
ly associated with immune activation and neuroinﬂammation.
IFNg, which is known to activate nitric oxide production by
macrophages (Chao et al., 1992; Spencer et al., 2016), is also able to
activate nitric oxide production by microglial cells (Fig. 3) and a
marked decrease on neuronal survival (Chao et al., 1992) (Fig. 3).
By analogy, astrocytes may be activated by IFNg, eventually
leading to neurodegeneration, as demonstrated by Lee et al. who
showed that conditioned media from human astrocytes treated
with IFNg leads to reduced viability loss of a human neuroblasto-
ma (SH-SY5Y) cell line (Lee et al., 2013). The potential role of
astrocytes in neurodegeneration is known to be mediated by their
secretion of IL-6, glutamate, proteases, oxygen-free radicals and
prostaglandins (Lee et al., 2013). These ﬁndings complement
previous work showing that activation of astrocytes by IFNg,
together with IL-1b, leads to the production of TNFa (Chung and
Benveniste,1990). Glial activation, with the resultant production of
pro-inﬂammatory mediators is a classical component of neuro-
inﬂammation, a chronic condition that leads to neuronal damage
and loss. Due to its ability to induce neuroinﬂammation, IFNg has
been implicated in a number of neurodegenerative diseases, as will
be discussed below.
3.3.2.1. Parkinson's disease. Parkinson's disease is characterized by
dopaminergic cell loss in the substantia nigra and striatum, leading
primarily to motor deﬁcits but also impacting on emotional
behaviours. Reports that blood levels of IFNg are elevated in
Parkinson's patients and parkinsonian monkeys (Barcia et al.,
2012; Mount et al., 2007; Reale et al., 2009) prompted research on
the possible involvement of this cytokine in the pathophysiology of
Parkinson's disease. Notably, Barcia et al. demonstrated that IFNg
and TNFa act synergistically to induce chronic glial activation and
thus neurodegeneration typical of Parkinson's disease (Barcia et al.,
2012). Conversely, Mount et al. using an in vitro approach showed
lower microglial reactivity and reduced loss of substantia nigra and
striatal cell loss induced by the neurotoxin 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) in neural cell cultures derived
from IFNg KO mice. The importance of microglia for manifestation
of the deleterious effect of IFNg was shown by the fact that IFNg
was only effective in neuronal-microglia co-cultures. Similarly,
rotenone-induced death of dopaminergic neurons was only
observed in the presence of microglia, an effect prevented by
co-incubating with antibodies against IFNg (Mount et al., 2007). In
an in vivo study, Chakrabarty et al. treated postnatal day 2 mice
with intra-cerebroventricular adeno-virus expressing IFNg; as
adults, the animals exhibited marked calciﬁcations of the basal
ganglia and severe nigrostriatal degeneration and a reduced
number of tyrosine-hydroxylase positive neurons (Chakrabarty
et al., 2011).
3.3.2.2. Alzheimer's disease. Abnormal accumulations of
extracellular amyloid-b (Ab) deposits and hyperphosphorylation
of tau protein that form intracellular neuroﬁbrillary tangles are the
neuropathological hallmarks of Alzheimer's disease, the typicalclinical symptoms of which include memory deﬁcits that progress
to dementia (Querfurth and LaFerla, 2010).
The view that IFNg may be involved in this neurodegenerative
disease stems from observations by Blasko et al. who showed that
combined stimulation with IFNg and TNFa triggers the production
of Ab peptides in a human neuroblastoma cell line (Blasko et al.,
1999). In a subsequent report, the same authors showed that co-
stimulation of primary astrocytes or astrocytoma cells with either
IFNg and TNFa or IFNg with IL-1b (but not with TNFa or IL-1b
alone) increased the generation of Ab1–40 and Ab1–42 (Blasko et al.,
2000). Furthermore, Bate et al. showed that IFNg could also
sensitize cortical, cerebellar and SH-SY5Y neuroblastoma cells in
vitro to the neurotoxic actions of Ab1–42 (Bate et al., 2006).
The adoptive transfer of IFNg-producing Ab-speciﬁc-CD4 Th1
cells (but not Th2 or Th17 cells which do not express IFNg) into
APP/PS1 mice, a model for Azheimer's disease, was shown to
accelerate the appearance of disease markers, in parallel with
increased microglial activation, Ab deposition and cognitive
decline (Browne et al., 2013). Consistent with these ﬁndings,
transgenic mice that overexpresses amyloid precursor protein
(APP) and exhibit some pathological features of Alzheimer's
disease, were found to express higher levels of IFNg and IL-12 (and
decreased levels IL-4) in various areas of the cerebral cortex (Abbas
et al., 2002). In contrast, deletion of IFNgR in APP transgenic mice
was accompanied by reduced gliosis and Ab plaque burden
(Yamamoto et al., 2007).
Signalling through a pathway initiated by IL-12/IL23 may also
underlie the ability of IFNg to induce Alzheimer's disease
pathophysiology. IL-12 and IL-23 share a common sub-unit p40
that is increased in the CSF from Alzheimer's disease patients and
genetic deletion of this subunit or the administration of p40
antibodies reduces amyloid deposition and ameliorates the
cognitive deﬁcits displayed by APP 1 transgenic mice (Vom Berg
et al., 2012).
Despite the evidence summarized above, the role of IFNg in
Alzheimer's disease remains far from clear. This is exempliﬁed by
the fact that IFNg overexpression in the brain for 10 months is
accompanied by increased intracellular levels of Ab, a reduction of
phosphorylated tau and increased neurogenesis (Mastrangelo
et al., 2009). On the other hand, using two mouse models of
tauopathy (JNPL3 and rTg4510), Li et al. reported that adenoviral
transduced expression of IFNg expression increases tau phosphor-
ylation without aggravating tau pathology (Li et al., 2015).
Moreover, Baron et al. observed that small amounts of IFNg
enhanced neurogenesis in the DG and improved spatial learning
and memory in aged WT mice as well as in a mouse model of
Alzheimer's disease (Baron et al., 2008). In addition, expression of
murine IFNg in the brain of APP transgenic mice was found to
increase glial reactivity and decrease Ab burden (Chakrabarty
et al., 2010).
Many factors may underlie the apparent discrepancies with
respect to how IFNg may inﬂuence the pathophysiology of
Alzheimer's disease. Disease context, stage of pathogenesis, and
cellular/cytokine milieu may play role singly or in a combinatorial
manner. Since anti-inﬂammatory strategies, e.g. by administering
IL-10, appear to worsen plaque burden by blocking microglial
phagocytosis in mice cf. (Chakrabarty et al., 2015; Guillot-Sestier
et al., 2015), re-establishment of a proper immune response
balance, rather than straightforward anti-inﬂammatory therapies,
may hold the key to ameliorating this and other neurodegenerative
diseases.
3.3.2.3. Down syndrome. Although Down syndrome is primarily
considered to be a developmental disorder characterized by,
among others, disability and progressive memory loss, nearly all
Down's patients exhibit a neurodegenerative process that
S. Monteiro et al. / Progress in Neurobiology 156 (2017) 149–163 159resembles Alzheimer's disease from about the age of 40 (Lockrow
et al., 2012). The extra chromosome responsible for Down's
syndrome encodes the APP gene but also encodes several IFNg-
related genes. Thus, the brains of trisomic (Ts16) mice which serve
as a model of Down syndrome, display signiﬁcantly higher levels of
IFNg and Fas receptor (an apoptosis marker). In addition, cortical
neurons cultured from Ts16 mice express higher levels of caspase-
1 and exhibit altered calcium homeostasis and pH. Addition of
IFNg to these cells leads to caspase-1 activation and neuronal
apoptosis (Hallam et al., 2000). In line with these observations,
treatment of cortical neurons from Ts16 mice with anti-IFNg
antibodies promotes neuronal viability (Hallam and Maroun,
1998), indicating a role for IFNg in the neurodegenerative
processes found in Down's syndrome.
4. Concluding remarks
During the last decade, the ﬁeld of neuroimmunology has
challenged a central dogma, namely that barriers protect the
healthy brain from events in the peripheral immune system. The
present consensus is that, even under physiological conditions,
these barriers are selectively permeable and allow peripheral
immune cells to populate brain sites to facilitate immune
surveillance and, consequently, to inﬂuence higher brain function.
This review revisited key aspects of IFNg actions in the CNS and
attempted to integrate existing knowledge into the new frame-
work of physiological neuroimmune modulation of the CNS
(Fig. 2). We especially focused on the impact of IFNg on key
cellular and synaptic processes that underscore different behav-
ioural dimensions, many of which may be attributable to the
immunological properties of this cytokine within the unique
milieu of the brain (Fig. 3). On the other hand, it is interesting that
the anti-proliferative effects of IFNg on immune cells are seen to
extend to neurons, with consequences for cognitive processing
(Fig. 3). Another similarity may be seen in terms of the ability of
IFNg to activate macrophages in the periphery and microglia in the
CNS; the latter culminates in neuronal damage, a common event in
the pathophysiology of neurodegenerative diseases (Fig. 3). At the
same time, the impact of IFNg on neurotransmission and dendritic
morphology imply that, in addition to being a classical immune
cytokine, IFNg should also be regarded as a potent neuro-
modulatory molecule (Fig. 3).
Despite our efforts to compile a comprehensive and clear
review of IFNg action in the brain, the subject is still cloaked by
ambiguity, especially because of the many contradictory reports.
The latter may reﬂect differences in experimental conditions (e.g.
in vivo versus in vitro, brain region analyzed, and the timing, mode
of administration and doses of IFNg used). The issue of IFNg dose
can be illustrated by the fact that the cytokine can induce or inhibit
a neuroprotective phenotype in astrocytes, depending on the
amount of cytokine administrated: while low amounts of IFNg
induce the release of substances associated with neuroprotection
and enhanced glutamate clearance capacity, higher does produce
the opposite effect (Garg et al., 2009).
Notably, while many studies describe a direct effect of IFNg
action in the brain parenchyma, they do not consider the complex
network of neuroimmune interactions that occur in the vicinity of
the brain and their potentially important implications for brain
function. This is well exempliﬁed by the crucial role of IFNg in
regulating the entry of surveying/supportive immune cells across
the CP. Lastly, it would appear that properly balanced brain
immunity is crucial for optimal brain function. Once the
differential and multiplicity of IFNg actions are better understood,
there would be strong potential for targeting IFNg (or its
downstream mechanisms) to ameliorate a number of neuropsy-
chiatric and neurological disorders.Conﬂict of interest
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